In the T2D primary care cohort, treatment approaches included metformin (42%), insulin (7%), GLP-1 analogs (7%), iSGLT2 (9%), iDPP-IV (11%), sulfonylureas (7%) and diet only (17%). Here, INS is linked to type 2 diabetes mellitus.